Research Notes and Ideas

Prior Ideas

Sanofi Invests in NLRP3 (VTYX) & FDA Countdown is on (ENTX)

Toe In The Water Last month, Ventyx Biosciences (Nasdaq...

October 7, 2024

An Early New Year's "Rezolution"; Don't Miss Rezolute (RZLT) Again

Fighting Laziness It can be difficult to objectively an...

September 23, 2024

Soleno (SLNO) Takes Center Stage, Delcath (DCTH) & Data, and Modular (MODD) "Almost" There...

Must Watch Biotech Theatre Over our past few notes, we ...

September 4, 2024

Xenon (XENE), Delcath (DCTH), Protara (TARA) and Other Q2 Musings

Pipeline in a Drug & A Real Pipeline Xenon Pharmace...

August 14, 2024

Managing Expectations: Cellectar (CLRB) & Delcath (DCTH)

Cellectar Biosciences (Nasdaq: CLRB) was a topical name...

July 30, 2024

Cellectar's (CLRB) Next Big Milestone, Can Satellos (MSCL) Play Well With Sarepta (SRPT)? and Ventyx (VTYX) Reeling

Let The Stock Breathe Cellectar Biosciences (Nasdaq: CL...

June 23, 2024

Ventyx (VTYX): An Emerging NLRP3 Pure-Play With Some Legacy Baggage

Four months ago, privately held NodThera Limited announ...

June 5, 2024

Optimism on Multiple Fronts

Optimism on Multiple Fronts We previously highlighted t...

May 23, 2024

Watch out Dupixent, Here Comes........Nektar (NKTR)?......Eupraxia (EPRX)?

Reason for Optimism? We have discussed Nektar Therapeut...

May 8, 2024

Entera (ETNX) & Protara (TARA), Bones and Bladders

Bones and Bladders In our initial note on Entera Bio (N...

April 24, 2024

A Little of Everything, Pain (XENE), Obesity (VERU), Radiopharmaceuticals (CLRB), and a High-Stakes Data Readout

Structure Matters Investors ignore structure at their p...

April 3, 2024

NKTR, Obesity, and OPTN (OptiNose): A Binary Bet Worth Taking?

In a September 2023 note, we highlighted Nektar Therape...

March 14, 2024

Rybelsus Redux: Entera Bio (Nasdaq: ENTX) & Oral GLP-1s for Obesity

Over our last few notes, we have thrown around some mic...

February 28, 2024

A Quick, Pre-Super Bowl, Update On A Few Names In Our Universe

Long-tenured Xenon Pharmaceutical (Nasdaq: XENE) shareh...

February 11, 2024

Adage and Perceptive's Curious GLP-1 Bet

What we are about to present is a trade idea. It land...

January 28, 2024

Cellectar (CLRB) Delivers at JPM and a New(ish) Name

Last Monday, Cellectar Biosciences (Nasdaq: CLRB) repor...

January 15, 2024

Names We're Watching in 2024

Xenon Pharmaceuticals (Nasdaq: XENE) Xenon always issue...

January 1, 2024

Protara Therapeutics

A respected biotech executive, and active investor, we ...

December 17, 2023

Follow-Up Note on Xenon & Fennec a Commercial Name to Watch

Xenon Cashed Up For Depression, Epilepsy, and Maybe Mor...

December 3, 2023

XENE: A Name From The Past

Over the past few years, we have frequently written on ...

November 5, 2023

Reviewing CLRB Ahead of Ph3 Data

A Trend We’re Following To tranche or not to tranche ...

October 21, 2023

Delcath: A Name From The Past

Recently a portfolio manager friend, Eden Rahim of Next...

October 9, 2023

Follow up on SLNO, OCUP, APLIF; and a new Idea (ANEB)

Follow-up From Our Last Note In our last note, we highl...

October 1, 2023

Satellos Biosciences

Satellos in Four Sentences: Satellos Biosciences is t...

September 11, 2023

September Ideas

A New Name We’re Watching For those who love negative...

September 4, 2023

GANX

Concise Investment Rationale Gain has an AI-enabled dru...

May 1, 2023

Bloom Burton Conference Recap

The Bloom Burton Healthcare Conference in Toronto is an...

April 28, 2023

Delcath, Ocuphire and Perimeter Medical

2022 was a very challenging year for life science inves...

February 28, 2023

Xenon Pharma

Of all the names in our coverage universe Xenon (Nasdaq...

July 19, 2022

Modular Medical

Modular Medical (Nasdaq: MODD) has had an eventful 1H22...

June 13, 2022

Ocuphire Pharma

Over the coming weeks we will be providing updates on m...

May 24, 2022

Manchester Management

An interview with Jeb Besser, Managing Member at Manche...

March 7, 2022

Social Capital LP

In January 2022, Social Capital made a C$43.4 million s...

February 14, 2022

Rosalind Advisors

An interview with Gil Aharon of Rosalind Advisors, wher...

December 13, 2021

Findell Capital

An interview with Brian Finn, Founder and CIO of Findel...

November 30, 2021

George W. Haywood

An interview with George Haywood, a well-known investor...

November 10, 2021

Delcath Systems

An interview with Gerard Michel, CEO of Delcath Systems...

October 25, 2021

Bright Minds Bio

An interview with Gideon Shapiro, Co-Founder & VP o...

October 11, 2021

Nervgen Pharma

NervGen is not an investment for the faint of heart, bu...

September 12, 2021

Sept 6, 2021

We generally don’t focus on the macro when writing ou...

September 6, 2021

Epigenomics AG

Virtual 1×1 Webinar with Epigenomics AG (ECX.DE, E...

July 12, 2021

Delcath Systems

Key Opinion Leader Conference Call with Dr. Jonathan Za...

July 12, 2021

Essa Pharma

We believe Big Pharma’s familiarity with AR antag...

July 12, 2021

Modular Medical

As the company “Pivots” from development to commerc...

June 7, 2021

March 7, 2021

We thought it timely to provide an update on our covera...

March 7, 2021

Processa Pharma

We believe by 2023, Processa could have one, or more, p...

February 22, 2021

Ocuphire Pharma

Low Science / High Science, Low Risk / High Risk, Ocuph...

November 9, 2020

July 26, 2020

Since our last update note in January, we have initiate...

July 26, 2020

Epigenomics AG

We believe there is tremendous upside for investors by ...

June 17, 2020

Delcath Systems

We believe Delcath’s $50mm market cap today is a refl...

May 19, 2020

TLC

We believe TLC can achieve a market cap of ~400mm this ...

April 27, 2020

Jan 16, 2020

Over the past 3-months we have initiated coverage on th...

January 16, 2020

Acasti Pharma

We are initiating on Acasti Pharma as a high risk inves...

November 25, 2019

Xenon Pharma

We believe through clinical success with their lead ass...

October 16, 2019